Quantifying the Value of Introducing an Oral Drug Delivery Option for Edaravone: A Review of Analyses Evaluating the Economic Impact of Oral versus Intravenous Formulations.

Ronquest, Naoko A; Paret, Kyle; Lucas, Aaron; Ciepielewska, Malgorzata; Hagan, Melissa

Ronquest, Naoko A; Paret, Kyle; Lucas, Aaron; Ciepielewska, Malgorzata; Hagan, Melissa.

Afiliação

Ronquest NA; Health Economics, RTI Health Solutions, Research Triangle Park, Durham, NC, USA.
Paret K; Health Economics, RTI Health Solutions, Research Triangle Park, Durham, NC, USA.
Lucas A; Health Economics, RTI Health Solutions, Research Triangle Park, Durham, NC, USA.
Ciepielewska M; Medical Affairs-HEOR/RWE/Publications, Mitsubishi Tanabe Pharma America, Inc, Jersey City, NJ, USA.
Hagan M; Medical Affairs-HEOR/RWE/Publications, Mitsubishi Tanabe Pharma America, Inc, Jersey City, NJ, USA.

Clinicoecon Outcomes Res ; 14: 499-511, 2022.

Article em En | MEDLINE | ID: mdl-35923520

Palavras-chave

amyotrophic lateral sclerosis; cost-effectiveness analysis; cost-minimization; decision makers; formulation comparison

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Health_economic_evaluation / Prognostic_studies / Systematic_reviews Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google